Drugs and drug delivery strategies for treatment of pulmonary arterial hypertension / 药学学报
Acta Pharmaceutica Sinica
; (12): 1332-1342, 2021.
Article
in Zh
| WPRIM
| ID: wpr-887076
Responsible library:
WPRO
ABSTRACT
Pulmonary arterial hypertension (PAH), also named as a cancer of cardiovascular disease, is a rare disease and has complicated pathogenesis. Recently, there are more understandings of PAH pathogeneses. According to the pathogenesis and active pathways, the clinically used drugs are classified into several groups incluidng prostacyclin analogues and prostacyclin receptor agonists, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase inhibitors, etc. To elevate the efficacy of the drugs, numerous drug delivery systems are developed. This review mainly summarized the pathological mechanism of PAH, drugs and drug delivery approaches in the treatment of PAH.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Acta Pharmaceutica Sinica
Year:
2021
Type:
Article